Tumor volume estimation and quasi- continuous administration for most effective bevacizumab therapy

Johanna Sápi, L. Kovács, Dániel András Drexler, Pál Kocsis, Dávid Gajári, Z. Sápi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. Materials and Methods We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal adenocarcinoma. In both cases, three groups were compared in the experiments. The first group did not receive therapy, the second group received one 200 Ig bevacizumab dose for a treatment period (protocol-based therapy), and the third group received 1.1 Ig bevacizumab every day (quasi-continuous therapy). Tumor volume measurement was performed by digital caliper and small animal MRI. The mathematical relationship between MRI-measured tumor volume and mass was investigated to estimate accurate tumor volume using caliper-measured data. A two-dimensional mathematical model was applied for tumor volume evaluation, and tumor- and therapy-specific constants were calculated for the three different groups. The effectiveness of bevacizumab administration was examined by statistical analysis. Results In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly smaller tumor volume compared to the no treatment group; however, there was a significant difference between untreated mice and mice who received quasi-continuous therapy (p =0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038). When the tumor has a symmetrical, solid closed shape (typically without treatment), volume can be evaluated accurately from caliper-measured data with the applied two-dimensional mathematical model. Conclusion Our results provide a theoretical background for a much more effective bevacizumab treatment using optimized administration.

Original languageEnglish
Article numbere0142190
JournalPLoS One
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 5 2015

Fingerprint

Tumor Burden
Tumors
therapeutics
neoplasms
adenocarcinoma
Adenocarcinoma
Clinical Protocols
calipers
Therapeutics
Group Psychotherapy
Neoplasms
Magnetic resonance imaging
Theoretical Models
mice
mathematical models
Mathematical models
dosage
Bevacizumab
Volume measurement
Human Activities

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Tumor volume estimation and quasi- continuous administration for most effective bevacizumab therapy. / Sápi, Johanna; Kovács, L.; Drexler, Dániel András; Kocsis, Pál; Gajári, Dávid; Sápi, Z.

In: PLoS One, Vol. 10, No. 11, e0142190, 05.11.2015.

Research output: Contribution to journalArticle

Sápi, Johanna ; Kovács, L. ; Drexler, Dániel András ; Kocsis, Pál ; Gajári, Dávid ; Sápi, Z. / Tumor volume estimation and quasi- continuous administration for most effective bevacizumab therapy. In: PLoS One. 2015 ; Vol. 10, No. 11.
@article{ff765115eee04802afacf70f5f66ae6b,
title = "Tumor volume estimation and quasi- continuous administration for most effective bevacizumab therapy",
abstract = "Background Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. Materials and Methods We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal adenocarcinoma. In both cases, three groups were compared in the experiments. The first group did not receive therapy, the second group received one 200 Ig bevacizumab dose for a treatment period (protocol-based therapy), and the third group received 1.1 Ig bevacizumab every day (quasi-continuous therapy). Tumor volume measurement was performed by digital caliper and small animal MRI. The mathematical relationship between MRI-measured tumor volume and mass was investigated to estimate accurate tumor volume using caliper-measured data. A two-dimensional mathematical model was applied for tumor volume evaluation, and tumor- and therapy-specific constants were calculated for the three different groups. The effectiveness of bevacizumab administration was examined by statistical analysis. Results In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly smaller tumor volume compared to the no treatment group; however, there was a significant difference between untreated mice and mice who received quasi-continuous therapy (p =0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038). When the tumor has a symmetrical, solid closed shape (typically without treatment), volume can be evaluated accurately from caliper-measured data with the applied two-dimensional mathematical model. Conclusion Our results provide a theoretical background for a much more effective bevacizumab treatment using optimized administration.",
author = "Johanna S{\'a}pi and L. Kov{\'a}cs and Drexler, {D{\'a}niel Andr{\'a}s} and P{\'a}l Kocsis and D{\'a}vid Gaj{\'a}ri and Z. S{\'a}pi",
year = "2015",
month = "11",
day = "5",
doi = "10.1371/journal.pone.0142190",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Tumor volume estimation and quasi- continuous administration for most effective bevacizumab therapy

AU - Sápi, Johanna

AU - Kovács, L.

AU - Drexler, Dániel András

AU - Kocsis, Pál

AU - Gajári, Dávid

AU - Sápi, Z.

PY - 2015/11/5

Y1 - 2015/11/5

N2 - Background Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. Materials and Methods We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal adenocarcinoma. In both cases, three groups were compared in the experiments. The first group did not receive therapy, the second group received one 200 Ig bevacizumab dose for a treatment period (protocol-based therapy), and the third group received 1.1 Ig bevacizumab every day (quasi-continuous therapy). Tumor volume measurement was performed by digital caliper and small animal MRI. The mathematical relationship between MRI-measured tumor volume and mass was investigated to estimate accurate tumor volume using caliper-measured data. A two-dimensional mathematical model was applied for tumor volume evaluation, and tumor- and therapy-specific constants were calculated for the three different groups. The effectiveness of bevacizumab administration was examined by statistical analysis. Results In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly smaller tumor volume compared to the no treatment group; however, there was a significant difference between untreated mice and mice who received quasi-continuous therapy (p =0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038). When the tumor has a symmetrical, solid closed shape (typically without treatment), volume can be evaluated accurately from caliper-measured data with the applied two-dimensional mathematical model. Conclusion Our results provide a theoretical background for a much more effective bevacizumab treatment using optimized administration.

AB - Background Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. Materials and Methods We have examined C38 mouse colon adenocarcinoma and HT-29 human colorectal adenocarcinoma. In both cases, three groups were compared in the experiments. The first group did not receive therapy, the second group received one 200 Ig bevacizumab dose for a treatment period (protocol-based therapy), and the third group received 1.1 Ig bevacizumab every day (quasi-continuous therapy). Tumor volume measurement was performed by digital caliper and small animal MRI. The mathematical relationship between MRI-measured tumor volume and mass was investigated to estimate accurate tumor volume using caliper-measured data. A two-dimensional mathematical model was applied for tumor volume evaluation, and tumor- and therapy-specific constants were calculated for the three different groups. The effectiveness of bevacizumab administration was examined by statistical analysis. Results In the case of C38 adenocarcinoma, protocol-based treatment did not result in significantly smaller tumor volume compared to the no treatment group; however, there was a significant difference between untreated mice and mice who received quasi-continuous therapy (p =0.002). In the case of HT-29 adenocarcinoma, the daily treatment with one-twelfth total dose resulted in significantly smaller tumors than the protocol-based treatment (p = 0.038). When the tumor has a symmetrical, solid closed shape (typically without treatment), volume can be evaluated accurately from caliper-measured data with the applied two-dimensional mathematical model. Conclusion Our results provide a theoretical background for a much more effective bevacizumab treatment using optimized administration.

UR - http://www.scopus.com/inward/record.url?scp=84951304594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951304594&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0142190

DO - 10.1371/journal.pone.0142190

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0142190

ER -